The additional value of myocardial T1ρ mapping to T1 and T2 mapping for predicting subsequent cancer therapy-related cardiac dysfunction in breast cancer patients who received anthracyclines with/without trastuzumab

• Published in: European journal of radiology 2024-12, Vol.181, p.111755, Article 111755
• Main Authors: Li, Xiaoqin, Shen, Hesong, Peng, Yangling, Miao, Zhiming, Tu, Chunrong, Zhang, Xiaoyong, Wu, Zhigang, Zeng, Xiaohua, Zhang, Jiuquan
• Format: Article
• Language: English
• Subjects: Adult; Aged; Anthracyclines - adverse effects; Antineoplastic Agents, Immunological - adverse effects; Breast neoplasms; Breast Neoplasms - diagnostic imaging; Breast Neoplasms - drug therapy; Cardiotoxicity; Cardiotoxicity - diagnostic imaging; Female; Heart; Heart Diseases - chemically induced; Heart Diseases - diagnostic imaging; Humans; Magnetic resonance imaging; Magnetic Resonance Imaging - methods; Middle Aged; Predictive Value of Tests; Prospective Studies; Trastuzumab - adverse effects
• ISSN: 0720-048X; 1872-7727; 1872-7727
• DOI: 10.1016/j.ejrad.2024.111755

•T1ρ, T1 and T2 values increased after anthracyclines with/without trastuzumab administration in breast cancer patients.•T1ρ and T1 changes from baseline to 3 months were associated with subsequent CTRCD.•Myocardial T1ρ mapping offers additional predictive value for subsequent CTRCD in breast cancer patients. We aimed to describe changes in parameters derived from myocardial T1ρ, T1, and T2 mapping and assess whether incorporating T1ρ mapping improves the predictive performance of T1 and T2 mapping for subsequent cancer therapy-related cardiac dysfunction (CTRCD) in breast cancer patients treated with anthracyclines with/without trastuzumab. From March 2021 to May 2023, 82 participants with breast cancer treated with anthracyclines with/without trastuzumab were prospectively recruited. Cardiac magnetic resonance was performed at baseline, 3 and 6 months in relation to baseline. T1ρ, T1 and T2 values were measured and compared by repeated measures analyses of variance. Logistic regression and receiver operating characteristic analysis were used to assess the performance in predicting subsequent CTRCD. Nineteen (23.17 %) participants developed CTRCD. T1ρ and T1 values progressively increased over time (all p